@onclive.bsky.socialThe EMA's CHMP offered a positive opinion recommending the approval of teclistamab for the treatment of adult patients with R/R multiple myeloma who have received at least 1 prior therapy #mmsm #oncology
Read more: www.onclive.com/view/chmp-re...
@onclive.bsky.social๐ช๐บ @ema.europa.eu's CHMP recommended EU approval of adjuvant T-DXd monotherapy for patients with resected HER2+ breast cancer with residual invasive disease after neoadjuvant taxane-based and HER2-targeted therapy. #bcsm #oncology
Full details โก๏ธ: www.onclive.com/view/chmp-re...
@onclive.bsky.social๐ฌ"The fact that we have patients out 5 years corroborates that this could have a big impact for this disease," said Udai S. Kammula, MD, FACS, of @upmchillmancc.bsky.social on TIL therapy outcomes in metastatic uveal melanoma.
Read more here ๐ค: www.onclive.com/view/tumor-r...
@onclive.bsky.social๐ช๐บ The CHMP has has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer, based on the phase 3 ROSELLA trial.
Full details โก๏ธ: onclive.com/view/chmp-re...
@onc-rg.bsky.social
@onc-rg.bsky.socialJoin our team as we break down the major readouts from WCLC 2026 and discuss what key signals to watch for as we head into ESMO 2026!
Register: events.teams.microsoft.com/event/681070...
@coherebtmi792.bsky.socialRapid Expansion and Innovation in the Liquid Biopsy Market
Read full blog on our website:
www.coherentmarketinsights.com/market-insig...
#CoherentMarketInsights #LiquidBiopsyMarket #CancerDiagnostics #PrecisionMedicine #HealthcareInnovation #MedicalTechnology #Oncology #Biotech
@4040rec.bsky.social@4040rec.bsky.social
@aiinmeditech.bsky.socialExplore our latest case study on HCP perceptions of Precision Oncology, Immunotherapy, CAR-T Cell Therapy, Liquid Biopsy, ADCs, and AI in Oncology.
Read more: www.sperresearch.com/Case-Studies...
#Oncology #PrecisionOncology #HCPInsights #SperMarketResearch
@onclive.bsky.socialCHMP of the EMA issued a positive opinion supporting melflufen plus dexamethasone for the treatment of multiple myeloma after at least 2 prior lines of therapy that is refractory to lenalidomide and to the last line of therapy. #mmsm #oncology
www.onclive.com/view/chmp-re...
@onclive.bsky.social๐ "This was the third line of treatment for pancreatic cancer, which is typically a refractory population, [thus] a 37% ORR is quite significant," said @bhuffmanmd.bsky.social of @danafarber.bsky.social on phase 1 data for INCB161734
Read more here ๐ฐ: onclive.com/view/phase-1...
@aspho-hq.bsky.socialResearch & Recommendations from #PediatricBloodandCancer: An [Imperfect] Case for #Dyadic #Research in #Pediatric Psychosocial #Oncology. #StephanieNanos #PHODocs #PedsHemeOnc buff.ly/17M9Ca2
@dralhilali.comWe talk about โthe cure for cancerโ as if weโre still waiting for it. But we already cure cancers every day. The real question is: why can we cure some cancers, but not others - and how do we change that?
#Cancer #CancerResearch #Oncology #CancerAwareness
@onclive.bsky.social๐ The primary end point of CELESTIMO was met with mosunetuzumab plus lenalidomide showing a statistically significant PFS improvement vs rituximab plus lenalidomide in R/R follicular lymphoma.
Read more here ๐ฐ: onclive.com/view/mosunet...
@onclive.bsky.socialThe latest version of the NCCN Guidelines for multiple myeloma include a dedicated section on MRD assessments with recommendations for clinical practice. Dive into the latest MRD updates and updated treatment recommendations #mmsm #oncology www.onclive.com/view/updated...
@islb.infoSee the latest #LiquidBiopsy research at the ISLB 2026 Poster Tours in Madrid!
๐
7 Nov | 15:15โ16:00
๐
8 Nov | 15:00โ15:45
Explore new findings, emerging ideas & research from the global community.
๐๐ฒ๐ฎ๐ฟ๐ป ๐บ๐ผ๐ฟ๐ฒ โ islb-congress.info
@oxcerpc.bsky.social
@hemehub.bsky.social๐ก๐ Todayโs questions!
Swipe to see the answers and explanations!
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
@hemehub.bsky.social๐งฌ Facts about Smoldering Multiple Myeloma:
Genomic drivers of progression, APOBEC and AID activity, genomic risk scoring, and MAF/MAFB translocations.
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub